Abstract
EE78 A Cost-Effectiveness Analysis of Atezolizumab as Adjuvant Treatment Following Complete Resection and Platinum-Based Chemotherapy in Adult Patients With Early-Stage Non-Small Cell Lung Cancer With a High Risk of Recurrence
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have